SLXN — Silexion Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Silexion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 3.86 | 4.68 | 17.4 | 11.6 |
| Operating Profit | -3.86 | -4.68 | -17.4 | -11.6 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -3.46 | -5.08 | -16.5 | -11.9 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -3.49 | -5.11 | -16.5 | -11.9 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -3.49 | -5.11 | -16.5 | -11.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -3.49 | -5.11 | -16.5 | -11.9 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -48.2 | -70.6 | -109 | -8.96 |